134 related articles for article (PubMed ID: 9771957)
1. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma.
Lümmen G; Sperling H; Luboldt H; Otto T; Rübben H
Cancer Chemother Pharmacol; 1998; 42(5):415-7. PubMed ID: 9771957
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
Köpf-Maier P
Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
Korfel A; Scheulen ME; Schmoll HJ; Gründel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
Van Veldhuizen PJ; Faulkner JR; Lara PN; Gumerlock PH; Goodwin JW; Dakhil SR; Gross HM; Flanigan RC; Crawford ED;
Cancer Chemother Pharmacol; 2005 Jul; 56(1):39-45. PubMed ID: 15791454
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of bortezomib for patients with advanced renal cell carcinoma.
Kondagunta GV; Drucker B; Schwartz L; Bacik J; Marion S; Russo P; Mazumdar M; Motzer RJ
J Clin Oncol; 2004 Sep; 22(18):3720-5. PubMed ID: 15365068
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.
Schöffski P; Garcia JA; Stadler WM; Gil T; Jonasch E; Tagawa ST; Smitt M; Yang X; Oliner KS; Anderson A; Zhu M; Kabbinavar F
BJU Int; 2011 Sep; 108(5):679-86. PubMed ID: 21156020
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study.
Thompson JA; Kuzel T; Drucker BJ; Urba WJ; Bukowski RM
Clin Genitourin Cancer; 2009 Oct; 7(3):E58-65. PubMed ID: 19815483
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
Choueiri TK; Dreicer R; Rini BI; Elson P; Garcia JA; Thakkar SG; Baz RC; Mekhail TM; Jinks HA; Bukowski RM
Cancer; 2006 Dec; 107(11):2609-16. PubMed ID: 17075879
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Amato RJ; Morgan M; Rawat A
Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.
Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP
Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of taxol in patients with metastatic renal cell carcinoma.
Einzig AI; Gorowski E; Sasloff J; Wiernik PH
Cancer Invest; 1991; 9(2):133-6. PubMed ID: 1677827
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial.
Gams RA; Nelson O; Birch R
Cancer Treat Rep; 1986 Jul; 70(7):921-2. PubMed ID: 3521848
[No Abstract] [Full Text] [Related]
18. Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice.
Fichtner I; Pampillón C; Sweeney NJ; Strohfeldt K; Tacke M
Anticancer Drugs; 2006 Mar; 17(3):333-6. PubMed ID: 16520662
[TBL] [Abstract][Full Text] [Related]
19. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
[TBL] [Abstract][Full Text] [Related]
20. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
